Publicaciones en colaboración con investigadores/as de Brigham and Women's Hospital (20)

2024

  1. FAM222A, Part of the BET-Regulated Basal Endothelial Transcriptome, Is a Novel Determinant of Endothelial Biology and Angiogenesis - Brief Report

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 44, Núm. 1, pp. 143-155

2022

  1. Dysregulated Genes, MicroRNAs, Biological Pathways, and Gastrocnemius Muscle Fiber Types Associated With Progression of Peripheral Artery Disease: A Preliminary Analysis

    Journal of the American Heart Association, Vol. 11, Núm. 21, pp. e023085

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide

    Mayo Clinic Proceedings, Vol. 95, Núm. 7, pp. 1445-1453

2019

  1. Dapagliflozin and cardiovascular outcomes in type 2 diabetes

    New England Journal of Medicine, Vol. 380, Núm. 4, pp. 347-357

2017

  1. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade

    Journal of Thoracic Oncology, Vol. 12, Núm. 8, pp. 1268-1279

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

  3. Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer

    Cancer Discovery, Vol. 6, Núm. 9, pp. 1007-1021

2014

  1. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice

    Genes and Development, Vol. 28, Núm. 5, pp. 479-490

2013

  1. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

    Cancer Discovery, Vol. 3, Núm. 12, pp. 1355-1363

  2. Alogliptin after acute coronary syndrome in patients with type 2 diabetes

    New England Journal of Medicine, Vol. 369, Núm. 14, pp. 1327-1335

  3. Efficacy of BET bromodomain inhibition in KRAS-mutant non-small cell lung cancer

    Clinical Cancer Research, Vol. 19, Núm. 22, pp. 6183-6192

  4. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer

    PLoS ONE, Vol. 8, Núm. 11

2012

  1. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer

    Clinical Cancer Research, Vol. 18, Núm. 18, pp. 4973-4985

  2. Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, Núm. 22, pp. 8699-8704

  3. Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response

    Cancer Research, Vol. 72, Núm. 22, pp. 5921-5933

2010

  1. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene

    Cancer Research, Vol. 70, Núm. 23, pp. 9827-9836

  2. Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung Tumors

    Cancer Cell, Vol. 17, Núm. 6, pp. 547-559

2009

  1. HIF2α cooperates with RAS to promote lung tumorigenesis in mice

    Journal of Clinical Investigation, Vol. 119, Núm. 8, pp. 2160-2170